Ngā hua rapu kaituhi

1

Atherogenic lipid profiles and its management in patients with rheumatoid arthritis mā Nurmohamed, Michael T

I whakaputaina 2007

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
2

The increased cardiovascular risk in rheumatoid arthritis: when does it start? mā Nurmohamed, Michael T

I whakaputaina 2010

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
3

Are biologics more effective than classical disease-modifying antirheumatic drugs? mā Nurmohamed, Michael T, Dijkmans, Ben AC

I whakaputaina 2008

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
4

Cardiovascular risk management in rheumatoid arthritis: are we still waiting for the first step? mā Peters, Mike JL, Nurmohamed, Michael T

I whakaputaina 2013

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
5

Biologics, cardiovascular effects and cancer mā Damjanov, Nemanja, Nurmohamed, Michael T, Szekanecz, Zoltán

I whakaputaina 2014

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
6

Editorial: Comorbidity Burden in Rheumatic Diseases mā Nikiphorou, Elena, Nurmohamed, Michael T., Szekanecz, Zoltan

I whakaputaina 2018

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
7

Cardiovascular disease risk in immune-mediated inflammatory diseases: recommendations for clinical practice mā Agca, Rabia, Smulders, Yvo, Nurmohamed, Michael

I whakaputaina 2022

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
8

Cardiovascular Disease Risk in Rheumatoid Arthritis Anno 2022 mā Dijkshoorn, Bas, Raadsen, Reinder, Nurmohamed, Michael T.

I whakaputaina 2022

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
9

Management and evaluation of extra-articular manifestations in spondyloarthritis mā van der Horst-Bruinsma, Irene E., Nurmohamed, Michael T.

I whakaputaina 2012

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
10

Unresolved Questions in Rheumatology: Motion for Debate: The Data Support Evidence-Based Management Recommendations for Cardiovascular Disease in Rheumatoid Arthritis mā Solomon, Daniel H, Peters, Mike J L, Nurmohamed, Michael T, Dixon, Will

I whakaputaina 2013

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
11

Multicentric reticulohistiocytosis: a case report mā Farokhi, Azadèh, van Vugt, Richard M., Hoekzema, Rick, Nurmohamed, Michael T.

I whakaputaina 2018

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
12

$Clinical improvement of cardiac function in a patient with systemic lupus erythematosus and heart failure with preserved ejection fraction treated with belimumab$

Clinical improvement of cardiac function in a patient with systemic lupus erythematosus and heart failure with preserved ejection fraction treated with belimumab mā Baniaamam, Milad, Voskuyl, Alexandre E, Nurmohamed, Michael T, Handoko, M Louis

I whakaputaina 2021

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
13

Coagulation in gout: is there a link with disease activity? mā Vedder, Daisy, Gerritsen, Martijn, Meijers, Joost C. M., Nurmohamed, Michael T.

I whakaputaina 2022

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
14

Correction to: Coagulation in gout: is there a link with disease activity? mā Vedder, Daisy, Gerritsen, Martijn, Meijers, Joost C. M., Nurmohamed, Michael T.

I whakaputaina 2022

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
15

Use of methotrexate therapy is not associated with decreased prevalence of metabolic syndrome mā Raterman, Hennie G, Voskuyl, Alexandre E, Dijkmans, Ben AC, Nurmohamed, Michael T

I whakaputaina 2009

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
16

Confounding by Indication Probably Distorts the Relationship between Steroid Use and Cardiovascular Disease in Rheumatoid Arthritis: Results from a Prospective Cohort Study mā van Sijl, Alper M., Boers, Maarten, Voskuyl, Alexandre E., Nurmohamed, Michael T.

I whakaputaina 2014

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
17

Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment mā Choy, Ernest, Ganeshalingam, Kandeepan, Semb, Anne Grete, Szekanecz, Zoltán, Nurmohamed, Michael

I whakaputaina 2014

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
18

Management of cardiovascular risk in patients with rheumatoid arthritis: evidence and expert opinion mā van den Oever, Inge A.M., van Sijl, Alper M., Nurmohamed, Michael T.

I whakaputaina 2013

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
19

A neutrophil signature is strongly associated with increased cardiovascular risk in gout mā Vedder, Daisy, Gerritsen, Martijn, Nurmohamed, Michael T, van Vollenhoven, Ronald F, Lood, Christian

I whakaputaina 2020

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
20

The Impact of Biologics and Tofacitinib on Cardiovascular Risk Factors and Outcomes in Patients with Rheumatic Disease: A Systematic Literature Review mā Nurmohamed, Michael, Choy, Ernest, Lula, Sadiq, Kola, Blerina, DeMasi, Ryan, Accossato, Paola

I whakaputaina 2018

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:

Ngā hua rapu - Nurmohamed, Michael

Atherogenic lipid profiles and its management in patients with rheumatoid arthritis mā Nurmohamed, Michael T

The increased cardiovascular risk in rheumatoid arthritis: when does it start? mā Nurmohamed, Michael T

Are biologics more effective than classical disease-modifying antirheumatic drugs? mā Nurmohamed, Michael T, Dijkmans, Ben AC

Cardiovascular risk management in rheumatoid arthritis: are we still waiting for the first step? mā Peters, Mike JL, Nurmohamed, Michael T

Biologics, cardiovascular effects and cancer mā Damjanov, Nemanja, Nurmohamed, Michael T, Szekanecz, Zoltán

Editorial: Comorbidity Burden in Rheumatic Diseases mā Nikiphorou, Elena, Nurmohamed, Michael T., Szekanecz, Zoltan

Cardiovascular disease risk in immune-mediated inflammatory diseases: recommendations for clinical practice mā Agca, Rabia, Smulders, Yvo, Nurmohamed, Michael

Cardiovascular Disease Risk in Rheumatoid Arthritis Anno 2022 mā Dijkshoorn, Bas, Raadsen, Reinder, Nurmohamed, Michael T.

Management and evaluation of extra-articular manifestations in spondyloarthritis mā van der Horst-Bruinsma, Irene E., Nurmohamed, Michael T.

Unresolved Questions in Rheumatology: Motion for Debate: The Data Support Evidence-Based Management Recommendations for Cardiovascular Disease in Rheumatoid Arthritis mā Solomon, Daniel H, Peters, Mike J L, Nurmohamed, Michael T, Dixon, Will

Multicentric reticulohistiocytosis: a case report mā Farokhi, Azadèh, van Vugt, Richard M., Hoekzema, Rick, Nurmohamed, Michael T.

Clinical improvement of cardiac function in a patient with systemic lupus erythematosus and heart failure with preserved ejection fraction treated with belimumab mā Baniaamam, Milad, Voskuyl, Alexandre E, Nurmohamed, Michael T, Handoko, M Louis

Coagulation in gout: is there a link with disease activity? mā Vedder, Daisy, Gerritsen, Martijn, Meijers, Joost C. M., Nurmohamed, Michael T.

Correction to: Coagulation in gout: is there a link with disease activity? mā Vedder, Daisy, Gerritsen, Martijn, Meijers, Joost C. M., Nurmohamed, Michael T.

Use of methotrexate therapy is not associated with decreased prevalence of metabolic syndrome mā Raterman, Hennie G, Voskuyl, Alexandre E, Dijkmans, Ben AC, Nurmohamed, Michael T

Confounding by Indication Probably Distorts the Relationship between Steroid Use and Cardiovascular Disease in Rheumatoid Arthritis: Results from a Prospective Cohort Study mā van Sijl, Alper M., Boers, Maarten, Voskuyl, Alexandre E., Nurmohamed, Michael T.

Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment mā Choy, Ernest, Ganeshalingam, Kandeepan, Semb, Anne Grete, Szekanecz, Zoltán, Nurmohamed, Michael

Management of cardiovascular risk in patients with rheumatoid arthritis: evidence and expert opinion mā van den Oever, Inge A.M., van Sijl, Alper M., Nurmohamed, Michael T.

A neutrophil signature is strongly associated with increased cardiovascular risk in gout mā Vedder, Daisy, Gerritsen, Martijn, Nurmohamed, Michael T, van Vollenhoven, Ronald F, Lood, Christian

The Impact of Biologics and Tofacitinib on Cardiovascular Risk Factors and Outcomes in Patients with Rheumatic Disease: A Systematic Literature Review mā Nurmohamed, Michael, Choy, Ernest, Lula, Sadiq, Kola, Blerina, DeMasi, Ryan, Accossato, Paola

Ngā utauta rapu: